Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR) Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by β-lactam allergy. Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.
Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, Michigan, USA Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA jang@dmc.org david_vanduin@med.unc.edu.
Jocelyn Y
JY
Ang
Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, Michigan, USA Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.
Nahed
N
Abdel-Haq
Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, Michigan, USA Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.
Frank
F
Zhu
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Abrar K
0000-0002-0369-9094
AK
Thabit
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.
David P
DP
Nicolau
Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, New York, USA.
Michael J
MJ
Satlin
Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA jang@dmc.org david_vanduin@med.unc.edu.
David
0000-0003-4784-3227
D
van Duin
D000293:Adolescent; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D004342:Drug Hypersensitivity / Q000209:etiology; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity; D000078142:Tazobactam; D047090:beta-Lactams / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D002939:Ciprofloxacin; D000583:Amikacin; D010397:Penicillanic Acid; D000078142:Tazobactam
Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5
26003469
Trends Microbiol. 2011 Aug;19(8):419-26
21664819
Pharm World Sci. 1998 Aug;20(4):149-60
9762727
Infect Drug Resist. 2013 Nov 29;6:215-23
24348053
Clin Infect Dis. 2016 Jul 15;63(2):234-41
27098166
Am J Clin Pathol. 2007 Jul;128(1):32-4
17580270
Clin Infect Dis. 2007 Feb 1;44(3):357-63
17205441
Clin Infect Dis. 2007 Jan 1;44(1):79-86
17143821
Clin Microbiol Infect. 2010 Sep;16(9):1482-7
20002107
J Infect Dis. 2015 Apr 15;211(8):1326-33
25362196
Crit Care Med. 2008 Apr;36(4):1089-96
18379232
Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4
25092700
Science. 2000 May 19;288(5469):1251-4
10818002